Search

By Industry Solutions (2)
By Phase (1)
By Molecule Type (1)
By Therapeutic Area (3)
Covance Events (9)
Geography (3)
Keywords (10)

Filters

Showing results 337 - 352 of 91813 for .

Showing results 337 - 352 of 91813 for .

Ex Vivo Evaluation of Immune-Enhancement, in the Cynomolgus Monkey, in Response to In Vivo Exposure to Several Checkpoint Inhibitors
ACT 2016 -- Recent years have seen an increase in "checkpoint inhibitors" as potential therapies for a variety of malignancies. Checkpoints, such as the PD-1 cell surface proteins expressed on activated T cells, dendritic cells and Monocytes can induce apoptosis in activated T cells, when bound to their respective ligand. This mechanism can be exploited by certain malignancies to evade immune surveillance. However, blocking this interaction offers a mechanism for some anti-cancer therapies....
Development of an In Vitro Method for the Generation of Nonhuman Primate Cytokines as an Aid to the Establishment of Cytokine Multiplex Assays Used in Support of Preclinical Safety Assessment
ACT 2016 -- The evaluation of circulatory cytokines in the nonhuman primate (NHP) provides vital information on the status of the animal's immune system; particularly during safety evaluation studies for novel biotech products where an increased or adverse cytokine production may be a consideration. This work evaluates a procedure for the ethical generation of positive control cytokine samples produced by in vitro stimulation of NHP Peripheral Blood Mononuclear Cells (PBMCs) with various...
The Role of Receptor Occupancy Analysis During Preclinical Development of Biologics
SOT 2014 - Preclinical safety assessment of biopharmaceuticals provides many challenges, including the potential for the production of anti-drug antibodies (ADA) particularly when a human (or humanised) protein is administered to an animal system. ADA production may lead to loss of exposure and activity of the biotech product resulting in limited toxicology information.